Reminder: Invitation to Roche’s Virtual Hematology Investor Event Dienstag, 17. Juni 2025 - 15:05

We are pleased to invite investors and analysts to participate in our virtual event on Monday, 23 June 2025, to highlight new results from Roche's Hematology pipeline including Phase III (STARGLO) Columvi in R/R DLBCL 2-year data , first presented at the American Society of Clinical Oncology (ASCO) Annual Meeting from 30 May-3 June, 2025, Phase III (SUNMO) data for Lunsumio + Polivy in R/R DLBCL primary analysis, accepted as a late breaking abstract at the International Conference on Malignant Lymphoma (ICML) from 17-21 June 2025, Phase III (POLARGO) data for Polivy in R/R DLBCL selected for Plenary presentation at both the European Hematology Association (EHA) Congress from 12-15 June 2025 and ICML as well as Phase I/II (NXTAGE) data for NXT007 in Hemophilia A presented at the Congress of the International Society on Thrombosis and Haemostasis (ISTH) from 21-25 June 2025.

19:00 - 20:15 CEST / 18:00 - 19:15 BST

13:00 - 14:15 am EDT / 10:00 - 11:15 am PDT

The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 18:00 CEST on the day of the event. > click here

Agenda
Introduction
Bruno Eschli, Head of Investor Relations

Malignant Hematology Franchise Update
Charles Fuchs, SVP Global Head of Oncology and Hematology, Product Development

NHL: FL update; DLBCL: Lunsumio+Polivy - Ph III (SUNMO) Primary Analysis; Columvi - Ph III (STARGLO) 2y data
Charles Fuchs, SVP Global Head of Oncology and Hematology, Product Development

Non-Malignant Hematology Franchise Update
Daud Chaudry, Lifecycle Leader Hemophilia Bispecifics, Global Product Strategy

Hemophilia: NXT007 - Ph I/II (NXTAGE) Primary Analysis
Daud Chaudry, Lifecycle Leader Hemophilia Bispecifics, Global Product Strategy

Q&A

Access to virtual event (pre-registration required)

Please pre-register for our webinar here*.

Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.

A replay of the webcast will be available via > roche.com/investors

*privacy notice

Best regards,

Bruno Eschli
Head of Investor Relations

Rishard Salie
Investor Relations Officer

Jan-Philipp Schwarzhans
Investor Relations Officer

Roche Investor Relations

Dr. Bruno Eschli

Phone: +41 61 68-75284

e-mail: bruno.eschli@roche.com

Dr. Sabine Borngräber

Phone: +41 61 68-88027

e-mail: sabine.borngraeber@roche.com

Dr. Birgit Masjost

Phone: +41 61 68-84814

e-mail: birgit.masjost@roche.com

Investor Relations North America

Loren Kalm

Phone: +1 650 225 3217

e-mail: kalm.loren@gene.com